Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation

被引:90
作者
Kwak, HJ
Park, MJ
Park, CM
Moon, SI
Yoo, DH
Lee, HC
Lee, SH
Kim, MS
Lee, HW
Shin, WS
Park, IC
Rhee, CH
Hong, SI
机构
[1] Korea Inst Radiol & Med Sci, Lab Funct Genom, Lab Med & Clin Pathol, Seoul 139706, South Korea
[2] Natl Canc Ctr, Res Inst Hosp, Goyang 411769, Gyeonggi, South Korea
[3] Yonsei Univ, Wonju Coll Med, Dept Biochem, Wonju, South Korea
[4] Kwandong Univ, Coll Med, Dept Microbiol, Kangnung, South Korea
[5] Korea Inst Radiol & Med Sci, Dept Neurosurg, Seoul, South Korea
[6] Korea Inst Radiol & Med Sci, Lab Med & Clin Pathol, Seoul, South Korea
关键词
emodin; tyrosine kinase inhibitor; angiogenesis; vascular endothelial growth factor-A; KDR/FIk-1;
D O I
10.1002/ijc.21641
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Emodin (1,3,8-trihydroxy-6-methylanthraquinone), an active component in the root and rhizome of Rheum palmatum, is a tyrosine kinase inhibitor with a number of biological activities, including antitumor effects. Here, we examine the effects of emodin on vascular endothelial growth factor (VEGF)-A-induced angiogenesis, both in vitro and in vivo. lit vitro, emodin dose-dependently inhibits proliferation, migration into the denuded area, invasion through a layer of Matrigel and tube formation of human umbilical vein endothelial cells (HUVECs) stimulated with VEGF-A. Emodin also inhibits basic fibroblast growth factor-induced proliferation and migration of HUVECs and VEGF-A-induced tube formation of human dermal microvascular endothelial cells. Specifically, emodin induces the cell cycle arrest of HUVECs in the G(0)/G(1) phase by suppressing cyclin D1 and E expression and retinoblastoma protein phosphorylation, and suppresses Matrigel invasion by inhibiting the basal secretion of matrix metalloproteinase-2 and VEGF-A-stimulated urokinase plasminogen activator receptor expression. Additionally, emodin effectively inhibits phosphorylation of VEGF-A receptor-2 (KDR/Flk-1) and downstream effector molecules, including focal adhesion kinase, extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase, Akt and endothelial nitric oxide synthase. lit vivo, emodin strongly suppresses neovessel formation in the chorioallantoic membrane of chick and VEGF-A-induced angiogenesis of the Matrigel plug in mice. Our data collectively demonstrate that emodin effectively inhibits VEGF-A-induced angiogenesis in vitro and in vivo. Moreover, inhibition of phosphorylation of KDR/Flk-1 and downstream effector molecules is a possible underlying mechanism of the anti-angiogenic activity of emodin. Based on these data, we propose that an interaction of emodin with KDR/Flk-1 may be involved in the inhibitory function of emodin toward VEGF-A-induced angiogenesis in vitro and responsible for its potent anti-angiogenic in vivo. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:2711 / 2720
页数:10
相关论文
共 55 条
[21]  
Inser J. M., 1999, J CLIN INVEST, V103, P1231
[22]   EMODIN, A PROTEIN TYROSINE KINASE INHIBITOR FROM POLYGONUM-CUSPIDATUM [J].
JAYASURIYA, H ;
KOONCHANOK, NM ;
GEAHLEN, RL ;
MCLAUGHLIN, JL ;
CHANG, CJ .
JOURNAL OF NATURAL PRODUCTS, 1992, 55 (05) :696-698
[23]   Matrix metalloproteinases and their inhibitors in tumour growth and invasion [J].
Kähäri, VM ;
Saarialho-Kere, U .
ANNALS OF MEDICINE, 1999, 31 (01) :34-45
[24]  
Kim CW, 2002, CANCER RES, V62, P6312
[25]   Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-κB activation, IκB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells [J].
Kumar, A ;
Dhawan, S ;
Aggarwal, BB .
ONCOGENE, 1998, 17 (07) :913-918
[26]  
Liang J.-Wen, 1993, Journal of Food and Drug Analysis, V1, P251
[27]  
McMahon G, 2000, Oncologist, V5 Suppl 1, P3
[28]   Comparative structure-function analysis of VEGFR-1 and VEGFR-2 - What have we learned from chimeric systems? [J].
Meyer, RD ;
Rahimi, N .
TISSUE REMODELING, 2003, 995 :200-207
[29]   BIOLOGY AND BIOCHEMISTRY OF PROTEINASES IN TUMOR INVASION [J].
MIGNATTI, P ;
RIFKIN, DB .
PHYSIOLOGICAL REVIEWS, 1993, 73 (01) :161-195
[30]  
Min HY, 1996, CANCER RES, V56, P2428